Prima Biomed (PRR.AX) Initiates Phase I Melanoma Study In Australia

Source: Biospace.com, January 2016

SYDNEY, AUSTRALIA–(Marketwired – Jan 26, 2016) – Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial site for TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, to be conducted in Australia.

‘TACTI-mel’ (Two ACTive Immunotherapeutics in melanoma) is a multicentre, open label, Phase I study in which patients with unresectable or metastatic melanoma will be dosed with IMP321 in combination with an approved checkpoint inhibitor. The study will evaluate safety as the primary endpoint and anti-tumour activity and the immune response to the combination as secondary endpoints.

The first clinical site, the Gallipoli Medical Research Foundation at the Greenslopes Private Hospital in Queensland, has been approved by the Australian Therapeutic Goods Administration (TGA). Recruitment for the trial can now commence under the direction of Dr. Victoria Atkinson, Principal Investigator for the trial. The TACTI-mel study will recruit up to 24 patients across 6 sites in Australia, with the first patients expected to be dosed in the first quarter of 2016.